RICADIME was a double-blind, sham-controlled randomised trial conducted in India that assigned 40 normotensive adults with type 2 diabetes and moderately or severely raised albuminuria to remote ischaemic conditioning or a sham procedure, once weekly for 8 weeks. Remote ischaemic conditioning means brief cycles of cuff inflation and release on a limb, producing short episodes of ischaemia and reperfusion, which has shown protective effects on distant organs in cardiac and stroke research.
Albuminuria fell by a median 37.9% (interquartile range -7.5 to 43.9) in the conditioning group and rose by 1.10% (-5.6 to 15.2) in the sham group (p=0.015). Serum creatinine fell from 1.0 to 0.83 mg/dL with conditioning while rising from 0.97 to 1.1 mg/dL with sham (p=0.0004), and mean estimated glomerular filtration rate (eGFR) rose from 85 to 99 mL/min/1.73 m2 (p=0.0001). HbA1c did not change. Mild arm pain in 10% was the only adverse effect.
The interest here is that this is a free, drug-free intervention aimed squarely at the outcome guidelines care about, a 30% or greater reduction in albuminuria as a marker of slowed progression to end-stage kidney disease. It also comes from an Indian centre, in a population where diabetic kidney disease presents earlier and access to newer nephroprotective drugs is uneven.
Nothing to do about it yet. Forty patients, eight weeks, a surrogate endpoint and an eGFR rise that large over two months should each prompt caution, and together they are decisive: this is research-stage, not a reason to start putting cuffs on patients. Watch for a larger and longer trial with hard kidney outcomes. In the meantime the proven steps for albuminuria are unchanged: an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at maximum tolerated dose, an SGLT2 inhibitor, and a non-steroidal mineralocorticoid receptor antagonist where albuminuria persists.
- Do not offer remote ischaemic conditioning outside a trial.
- Confirm albuminuria on two of three samples before acting on any single urine albumin-to-creatinine ratio result.
- Check the angiotensin-converting enzyme inhibitor or angiotensin receptor blocker is at maximum tolerated dose before adding anything else.
- Add an SGLT2 inhibitor for albuminuric kidney disease unless contraindicated.
- Recheck the urine albumin-to-creatinine ratio three to four months after any change; it is the response measure.
The statistics, in plain English
The albuminuria result is a median with an interquartile range running from -7.5% to 43.9%, meaning at least a quarter of the conditioning group actually got worse. The average moved; not everybody did. With 20 patients per arm the trial can only detect large effects, and large effects found in small trials are usually smaller when the study is repeated at scale. The eGFR rise from 85 to 99 over eight weeks is not biologically plausible as real nephron recovery and most likely reflects the fall in creatinine driving a calculated number, so read it as a statement about creatinine rather than about kidney function. Albuminuria is itself a surrogate: reductions usually, but not always, translate into fewer people reaching dialysis.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free